Overall pros - definitely better than theatrical release, better character dev, cooler teaser moments
Overall cons - Some exposition material that didn't add much value in the first half, some meh music moments
But honestly, I'm more intrigued by the story around how this happened than the movie itself. This is the first situation I'm aware of that had a fan campaign for a rerelease actually result in a big budget do-over. This petitions are always started and typically go nowhere.
I don't know that Snyder and WB will rekindle the marriage, or for that matter, that they want to. But the teasers within the movie (you who've watched it know what I mean) are much more interesting to me than anything DC has been trying to tantalize me with so far...
Make that dark precog'd movie, thanks.
Maybe HBO can negotiate holding on to #SnyderVerse while WB does its thing with recast Batman, Joker, et al
(Kinda like dividing the kids in a divorce, no?)
Full disclosure, I'm an MCU fanatic. But I want all comic franchises to succeed.
Exit observation. Remember when Wonder Woman (well received) before Justice League (not well received) was released a few months later in 2017?
Now a big reversal re Wonder Woman 1984 (not well received) preceded this #SnyderCut (well received so far) by a few months. 🤔🤔🤔
• • •
Missing some Tweet in this thread? You can try to
force a refresh
2/ If you've followed me a while, you know I believe it isn't the actual ingestion of cholesterol on #LowCarb that has a big impact on serum levels -- it's predominantly the trafficking of fat. (See CholesterolCode.com/model)
But this is actually a very testable distinction...
3/ All we need is an experiment where I consume a lot of (1) low fat food that still (2) has ample amounts of cholesterol.
Thus, the "processed meat" side of the experiment is key if it has a decent amount of cholesterol -- and it does.
If a drug did many of the same things with one's lipid profile as a #LowCarb diet, particularly decreasing triglycerides while increasing #LDL#Cholesterol:
1) Would it reduce ASCVD risk? 2) And if so, would it be more acceptable than #LowCarb?
2/ If you haven't heard, SGLT2 Inhibitors have recently emerged and have been gaining a lot of popularity. Data thus far shows they typically:
3/ Naturally, that has the attention for those of us interested in how triglyceride trafficking and turnover could be relevant to #LDL increasing for what may turn out to be non-pathogenic reasons (kinda my focus ;) )
2/ FH, particularly HoFH is highly associated with atherosclerosis and is considered a substantial risk.
Cases of HoFH are extremely rare, but are considered a cornerstone of the lipid hypothesis as many with LDL-C levels (comparable to Nick's) demonstrate CVD as children...
3/ Brown and Goldstein have seminal work on this topic.
2/ Per @Lpa_Doc's (2) and (3) in the thread, when we have "normal" TG levels (guidelines would say < 150, I prefer < 100) then most cholesterol in ApoB-containing lipoproteins (ApoB-Lp) are in LDL and there's little VLDL-cholesterol...
3/ But where TG is high, there's more utility in looking at ApoB given it lumps remnants (VLDL/IDL) with LDL.
-- But IMO, that's also the problem. We want to disentangle where remnant association is much more relevant than LDL association...